Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
Christina Woopen, Katharina Schleußner, Katja Akgün, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 18

Showing 18 citing articles:

Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?
Gianmarco Bellucci, Virginia Rinaldi, Maria Chiara Buscarinu, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 45
An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations
Bülent Kantarcıoğlu, Omer Iqbal, Joseph M. Lewis, et al.
Clinical and Applied Thrombosis/Hemostasis (2022) Vol. 28
Open Access | Times Cited: 21
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
Jeffrey A. Cohen, Robert A Bermel, Cynthia Grossman, et al.
Multiple Sclerosis Journal (2022) Vol. 28, Iss. 7, pp. 1131-1137
Open Access | Times Cited: 18
Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment
Christina Woopen, Marie Dunsche, Rocco Haase, et al.
Neurology Neuroimmunology & Neuroinflammation (2022) Vol. 9, Iss. 6
Open Access | Times Cited: 14
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
Aliya Jaber, Meera H. Patel, Andrew Sylvester, et al.
Neurology and Therapy (2023) Vol. 12, Iss. 2, pp. 687-700
Open Access | Times Cited: 8
Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab
Tjalf Ziemssen, Marie Groth, Benjamin Ettle, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2167-2167
Open Access | Times Cited: 13
T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy
Anthony T. Reder, Olaf Stüve, Stephanie Tankou, et al.
Multiple Sclerosis Journal (2022) Vol. 29, Iss. 6, pp. 648-656
Open Access | Times Cited: 12
SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma
Georges Katoul Al Rahbani, Christina Woopen, Marie Dunsche, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 684-684
Open Access | Times Cited: 2
Safety, immunogenicity, efficacy, and acceptability of COVID-19 vaccination in people with multiple sclerosis
Fioravante Capone, Mariagrazia Rossi, Alessandro Cruciani, et al.
Neural Regeneration Research (2022) Vol. Publish Ahead of Print
Open Access | Times Cited: 11
Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more
Victor Constantinescu, Katja Akgün, Tjalf Ziemssen
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 10, pp. 675-693
Closed Access | Times Cited: 11
Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses
Christina Woopen, Urszula Konofalska, Katja Akgün, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 9
Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)
Tjalf Ziemssen, Marie Groth, Benedict Rauser, et al.
Therapeutic Advances in Neurological Disorders (2022) Vol. 15, pp. 175628642211353-175628642211353
Open Access | Times Cited: 7
SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19
Ana Muñoz-Jurado, Begoña M. Escribano, Eduardo Agüera, et al.
Journal of Neurology (2022) Vol. 269, Iss. 9, pp. 4581-4603
Open Access | Times Cited: 7
Multiple sclerosis patients’ response to COVID-19 pandemic and vaccination in Egypt
Adel Hassanein Elsayed Gad, Sandra Ahmed, Mostafa Yahya Abdelmohsen Garadah, et al.
The Egyptian Journal of Neurology Psychiatry and Neurosurgery (2022) Vol. 58, Iss. 1
Open Access | Times Cited: 7
Worsening of the vitiligo following the second dose of the BNT162B2 mRNA COVID‐19 vaccine
Gökhan Okan, Pervin Vural
Dermatologic Therapy (2021) Vol. 35, Iss. 3
Open Access | Times Cited: 9
Acute cerebellitis requiring posterior fossa decompression after COVID-19 vaccination in an ocrelizumab-treated patient with multiple sclerosis
Gregor Brecl Jakob, Lina Savšek, Bernard Meglič
Neurological Sciences (2022) Vol. 43, Iss. 6, pp. 3509-3511
Open Access | Times Cited: 3
The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic
Maryam Azimzadeh, Nora Möhn, Sajjad Ghane Ezabadi, et al.
Biomolecules (2021) Vol. 11, Iss. 9, pp. 1372-1372
Open Access | Times Cited: 4
Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022
Christoph Friedli, Anke Salmen, Robert Hoepner, et al.
Clinical and Translational Neuroscience (2022) Vol. 7, Iss. 1, pp. 2-2
Open Access | Times Cited: 1
Page 1

Scroll to top